The short answer
A harmful low-pressure interaction between Crataegus monogyna and indapamide has not been established. Check the species and preparation with your pharmacist before use.
What this answer covers
Crataegus monogyna oral products, distinguished from C. laevigata, unidentified hawthorn species and fruit versus leaf-and-flower preparations.
- Supplement or preparation
- Crataegus monogyna
- Medication ingredient
- indapamide
Common-name hawthorn evidence has limits
A study reporting a small diastolic pressure reduction used Crataegus laevigata, a different species from C. monogyna. It did not demonstrate an indapamide-specific interaction. That result cannot be assigned automatically to your exact herb.
Other research does not settle the question
A short trial of a standardized leaf-and-flower extract found no dose-related pressure reduction. It excluded people taking blood-pressure medicines and did not clearly identify the species in its product description. It therefore cannot establish safety or a low-pressure interaction with indapamide.
Identify the product before using it
Check the Latin name, plant part, extraction details and other ingredients. The European monograph covers several hawthorn species and defined leaf-and-flower preparations; it is not a clinical test of every fruit extract or C. monogyna product. Ask your pharmacist to review the label.
Use your blood-pressure plan as the guide
Because indapamide lowers pressure, discuss adding hawthorn if your readings are already low or you have dizziness or near-fainting. There is no established indapamide-specific safe dose or hours-apart schedule. Seek assessment for fainting or persistent symptoms rather than treating them with another supplement.
Evidence and practical considerations
Side effects & toxicity
Exact C. monogyna co-use evidence does not establish increased hypotension risk with indapamide.
- Exact scope
- Crataegus monogyna oral products, distinguished from C. laevigata, unidentified hawthorn species and fruit versus leaf-and-flower preparations. with Exact indapamide RxCUI 5764 IN, confirmed by current NLM properties. Oral indapamide dose and release formulation are retained; evidence for hydrochlorothiazide, other diuretics or combination antihypertensive products is not automatically equivalent.
- Medication form and route
- Oral
What remains uncertain
- Positive adjacent research used C. laevigata; a short null trial excluded antihypertensive users and did not resolve species. Traditional-use monograph with no reported interactions is not proof of safety.
Factors that may matter: Dose and duration; Exact supplement preparation; Kidney function; Other medicines; Baseline electrolyte status.
Read the supporting source summaries
Source 1: Current U.S. prescribing information
dailymed.nlm.nih.gov · Source check Sep 10, 2026
Population: Patients prescribed oral indapamide 1.25 or 2.5 mg tablets; additional dose-ranging study data.
Recommends periodic electrolyte and renal-function assessment. Potassium reductions were dose-related; some low measurements normalized without intervention. Calcium increases in indapamide studies were only slight. Includes a thiazide-like magnesium-loss warning.
How this applies: Exact medication guidance with explicit dose and nutrient distinctions. Exact indapamide RxCUI 5764 IN, confirmed by current NLM properties. Oral indapamide dose and release formulation are retained; evidence for hydrochlorothiazide, other diuretics or combination antihypertensive products is not automatically equivalent.
A label class warning is not proof that every patient has magnesium depletion or that routine supplements are required. Higher-dose risks and other diuretics cannot be assigned to every low-dose regimen.
Source 2: Original clinical research
ebi.ac.uk · Source check Sep 10, 2026
Population: 21 adults with prehypertension or mild hypertension; antihypertensive users were excluded.
No significant dose-response in blood pressure or flow-mediated dilation; adverse symptoms were uncommon.
How this applies: Adjacent hawthorn evidence only; absence of exact identity and co-use limits applicability.
Very short study, no indapamide users, and botanical species not specified in the inspected product description. Cannot be promoted to exact C. monogyna evidence.
Source 3: Original clinical research
pubmed.ncbi.nlm.nih.gov · Source check Sep 10, 2026
Population: 79 adults with type 2 diabetes; 71% used hypotensive medicines.
Small average diastolic reduction, no significant systolic difference; no herb-drug interaction detected.
How this applies: Explains why common-name hawthorn evidence does not establish the exact C. monogyna claim.
C. laevigata is a different species; no exact indapamide subgroup. Average lowering is not demonstrated excess hypotension.
Source 4: Final regulatory herbal monograph
ema.europa.eu · Source check Sep 10, 2026
Population: Users of defined hawthorn leaf-and-flower preparations.
Traditional-use monograph lists no reported interactions. It is not evidence of a tested indapamide combination.
How this applies: Identity and preparation boundaries for exact C. monogyna.
The 2025 revision is still listed as draft and is not substituted for adopted guidance. No reported interactions does not establish safety. Species and preparations are not interchangeable.
Source 5: Authoritative medication terminology
rxnav.nlm.nih.gov · Source check Sep 10, 2026
Population: Medication terminology.
Identifies indapamide as IN.
How this applies: Exact medication identifier.
Does not establish formulation equivalence or a clinical interaction.
Research assessment: · Open full citations ↗
Review and change history
- Publication status
- Published research summary
- Clinical review
- Not yet recorded
| Date | Update |
|---|---|
| Article prepared | |
| Sources checked and article drafted. | |
| Research summary published |
Article revision: e593095f3a0a6333
This guide brings together the evidence records used by our interaction checker. Each finding retains its own preparation limits, research date, and source summaries.
Full citations require verification. Reading this answer and the source summaries does not.
Taking other supplements or medications?
Use the checker to explore your other combinations. Ask a pharmacist to review the exact products, amounts and medical conditions in your complete list.
Open the interaction checkerInformation, not medical advice. Do not change prescribed treatment based on this guide.